We collect cookies for vital website function and to better serve our customers. By continuing to browse you agree to the storing of cookies on your device. See our privacy policy for details.

Estrone-3-Glucuronide ELISA Kit

Item № 501290
     96 solid plate $245.00 0.00
     96 strip plate $245.00 0.00

Pricing updated 2019-05-25. Prices are subject to change without notice.

  • Measures estrone-3-glucuronide, the predominant metabolite of estradiol in biological matrices
  • Assay 24 samples in triplicate or 36 samples in duplicate
  • Lower limit of detection (LLOD) is 6.6 pg/ml
  • Rapid 2-hour or overnight incubation options
  • Estrone-3-Glucuronide EIA Kit
  • E1G

Estrone-3-glucuronide is the predominant metabolite of estradiol in urine and a urinary marker for the fertile window in women.1 Measurement of urinary glucuronides is a convenient, non-invasive method for detecting reproductive hormone levels compared to measuring plasma levels.2 Estrone-3-glucuronide, along with pregnanediol-3-glucuronide, are indicators of female reproductive health.2

Literature has shown high serum estrone levels, which directly correlate to urinary estrone-3-glucuronide levels, are associated with estrogen receptor-positive breast cancers.3 Hormone receptor status is the main factor in planning treatment and can be treated with hormone therapies, including tamoxifen and aromatase inhibitors.4 In addition to its role in breast cancer, circulating estrogens, including estrone metabolized from oral hormone replacement therapy, have been shown to increase thrombin generation leading to higher risk for blood clots, myocardial infarctions, deep vein thrombosis and strokes.5,6

Needed but not supplied: Please download the kit booklet to verify if UltraPure Water (Milli-Q or equivalent) or any other components are needed for this assay.

Recommended Products

Related Products
View Related Product Categories
Technical Information
  • Estrone-3-Glucuronide EIA Kit
  • E1G
Limit of Detection
6.6 pg/ml (overnight); 10.1 pg/ml (rapid)
Assay Range
2.7-6,000 pg/ml
23.2 pg/ml (overnight); 36.1 pg/ml (rapid)
125.6 pg/ml (overnight); 246.8 pg/ml (rapid)
Cross Reactivity
  • (100%) Estrone-3-Glucuronide
  • (133%) Estrone Sulfate
  • (0.1%) Estradiol Sulfate
Show all 12
  • Animal/Bovine
  • Animal/Rabbit

Warning - this product is not for human or veterinary use.

Shipping & Storage
Wet ice in continental US; may vary elsewhere
≥ 1 year
Downloads & Resources
Product Downloads

Download Kit Booklet

Download Safety Data Sheet (SDS)

Download free InChI Key generation software

Additional Information

View the Cayman Structure Database for chemical structure definitions for many Cayman products

Get Batch-Specific Data and Documents by Batch Number

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.

References & Product Citations
Product Description References

1. Eichner, S.F., and Timpe, E.M. Urinary-based ovulation and pregnancy: Point-of-care testing Ann. Pharmacother. 38(2), 325-331 (2004).

2. O'Connor, K.A., Brindle, E., Holman, D.J., et al. Urinary estrone conjugate and pregnanediol 3-glucuronide enzyme immunoassays for population research Clin. Chem. 49(7), 1139-1148 (2003).

3. Miyoshi, Y., Tanji, Y., Taguchi, T., et al. Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women Clin. Cancer Res. 9(6), 2229-2233 (2003).

4. Bagot, C.N., Marsh, M.S., Whitehead, M.I., et al. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapyexa J. Thromb. Haemost. 8(8), 1736-1744 (2010).

5. Karim, R.M., Mack, W.J., Hodis, H.N., et al. Influence of age and obesity on serum estradiol, estrone, and sex hormone binding globulin concentrations following oral estrogen administration in postmenopausal women J. Clin. Endocrinol. Metab. 94(11), 4136-4143 (2009).

6. Dong, M., Mu, N., Ren, F., et al. Prospective study of effects of endogenous estrogens on myocardial no-reflow risk in postmenopausal women with acute myocardial infarction J. Interv. Cardiol. 27(5), 437-443 (2014).

Technical Support
Contact Us
  • Toll Free Phone (USA and Canada Only): (888) 526-5351
  • Direct Phone: (734) 975-3888
Cayman Contract Services

We work with scientists to accelerate their research, drug discovery, and drug development needs through our expertise in the following areas:

Cayman Chemical

1180 East Ellsworth Road

Ann Arbor, Michigan 48108 USA

Toll Free: (800) 364-9897

(USA and Canada Only)

Fax: (734) 971-3640